Haema 2012; 3(1): 2-9
by Georgios Georgiou1, Photis Beris1,2
1Unilabs, Département d’Hématologie, Coppet Switzerland; 2Département de Médecine Interne, Faculté de Médecine, Université de Genève, Genève Suisse
Category: HAEMA 2012 (1)
Prognostic factors in CML and treatment choices
Haema 2012; 3(1): 10-22
by Maria Ν. Pagoni and Ifigeneia A. Tzannou
Department: Department of Hematology and Stem Cell Transplantation Unit, Evaggelismos General Hospital, Athens, Greece
Continue reading “Prognostic factors in CML and treatment choices”
First Line Treatment for Chronic Phase Chronic Myelogenous Leukemia (CP-CML): Treatment Options
Haema 2012; 3(1): 23-36
by Constantinos Tsatalas, Emmanouil Spanoudakis, Ioannis Kotsianidis
Department of Haematology, Democritous University of Thrace Medical School, Alexandroupolis
Criteria for treatment switch from imatinib to second generation TKIs
Haema 2012; 3(1): 37-44
by Nora-Athina Viniou, Panagiotis Diamantopoulos, Vassiliki Papadopoulou
1st Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, “Laiko” General Hospital, Athens
Continue reading “Criteria for treatment switch from imatinib to second generation TKIs”
The role of Stem Cell Transplantation in CML: For which patients and when
Haema 2012; 3(1): 45-56
by Ifigeneia Tzannou and Ioannis Baltadakis
Department of Hematology and Stem Cell Transplantation Unit, Evaggelismos General Hospital, Athens, Greece
Continue reading “The role of Stem Cell Transplantation in CML: For which patients and when”
Guidelines for the molecular monitoring of patients with CML treated with tyrosine kinase inhibitors
Haema 2012; 3(1): 57-64
by Tassoula Touloumenidou, Apostolia Papalexandri, Kostas Stamatopoulos
Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
CML stem cells: the pathway to CML cure?
Haema 2012; 3(1): 65-77
by Maria Dimou, Panayiotis Panayiotidis
1st Department of Propaedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, Greece
Classification and current prognostication of Myeloproliferative Neoplasms
Haema 2012; 3(1): 78-88
by Theodoros Marinakis, George Kanavos, Nikolaos I. Anagnostopoulos
Department of Clinical Hematology, General Hospital of Athens “G. Gennimatas”
Continue reading “Classification and current prognostication of Myeloproliferative Neoplasms”
Genetic aberrations in Ph negative myeloproliferative neoplasms
Haema 2012; 3(1): 89-98
by Georgios Georgiou, Vasiliki Mpartzi
Research Laboratory of APPK
Continue reading “Genetic aberrations in Ph negative myeloproliferative neoplasms”
Therapeutic management of Ph negative Myeloproliferative Neoplasms
Haema 2012; 3(1): 99-108
by Despoina Pantelidou, Maria Papaioannou
Haematology Unit of 1stDepartment of Internal Medicine, AHEPA University Hospital, Thessaloniki
Continue reading “Therapeutic management of Ph negative Myeloproliferative Neoplasms”